ClinicalTrials.gg
TerminatedNCT03437668Updated Oct 8, 2024Results posted

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

A Phase 2/3 interventional study of WSE and Placebo Oral Tablet in Schizophrenia, sponsored by Chengappa, K.N. Roy, MD. Terminated at 2 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Chengappa, K.N. Roy, MD · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Unable to reach enrollment target due to COVID

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
818th of 1,320
47 · median 66
Started
2018
with 47 others
Phase 2/3
22 of 1,466
1 open now
Registered
1,054th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 818th largest by enrollment of the 1,320 interventional ones that give a count, is one of 48 that started in 2018, is one of 22 in phase 2/3, and was the 1,054th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Withania Somnifera
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic and Statistical Manual (DSM) 5 diagnosis of schizophrenia or schizoaffective disorder
  • Ability to provide informed written consent
  • PANSS total score ≥ 70 or a CGI Severity Scored ≥ 4; and at least 2 positive symptom subscale items (i.e., delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility and unusual thought content) scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 = absent to 7 = extreme.
  • Evidence of a positive symptom exacerbation during the year prior to study entry.
  • For women of child bearing age, a negative serum pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Testing positive for illicit substances (positivity to marijuana or opioids will be assessed on a case by case basis due to the long elimination half life in the urine of marijuana and the use of opioids for various pain disorders, caffeine and nicotine are excepted)
  • Receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate, others) will be reviewed on a case by case basis
  • Seriously unstable medical illnesses
  • Pregnant or breast feeding women
  • Known allergy or history of serious adverse event with WSE
  • Subjects who may require imminent hospitalization (examples: suicidal or aggressive behavior)
  • Currently receiving antibiotics, anti-viral, or anti-parasitic medications
  • Currently receiving medications (e.g. oral scheduled , chemotherapy or transplantation or /AIDS associated drugs).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Withania Somnifera Extract (WSE)

    WSE 500 mg bid for 12 weeks

    Drug: WSE

  • Placebo comparator
    Placebo tablets

    Placebo oral tablet bid for 12 weeks

    Drug: Placebo Oral Tablet

Interventions

  • DrugAshwagandhaStudies of AshwagandhaAshwagandha pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    WSE tablets

    Also known as: Withania somnifera extracts, Ashwagandha, Sensoril®

  • DrugPlacebo Oral Tablet

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Positive and Negative Symptom Scale

    The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Subjects can not score lower than 30 or higher than 210. Higher score indicates higher amount of psychopathology

    Time frame: 12 weeks

Secondary outcomes

  1. PANSS Negative Factor Score Also Know as Marder Factors

    The Marder negative factor is a factor-analysis derived dimension of the Positive and Negative Syndrome Scale (PANSS) that measures negative symptoms of schizophrenia. It's made up of seven items from the PANSS, including: Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic withdrawal, Motor retardation, Active social avoidance, Lack of spontaneity in conversation. Each item is scored from 1 to 7 with a higher score indicating greater severity. Minimum score is 7 and maximum is 49

    Time frame: 12 weeks

07

Results

Posted Oct 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneWithania Somnifera Extract (WSE)Placebo Tablets
Started2423
Completed2019
Not completed44

Outcome measures

PrimaryPositive and Negative Symptom Scale

The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Subjects can not score lower than 30 or higher than 210. Higher score indicates higher amount of psychopathology

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
Positive and Negative Symptom Scale
score on a scaleWithania Somnifera Extract (WSE)Placebo Tablets
Week 065.0 ± 2.675.1 ± 2.6
Week 663.2 ± 2.472.0 ± 2.5
Week 1261.3 ± 2.768.8 ± 2.7
Statistical analysis
  • Withania Somnifera Extract (WSE) vs Placebo Tablets · Mixed Models Analysis · p = .31 (p-value is for the interaction of time and treatment group in the mixed model) · Slope: -0.22
SecondaryPANSS Negative Factor Score Also Know as Marder Factors

The Marder negative factor is a factor-analysis derived dimension of the Positive and Negative Syndrome Scale (PANSS) that measures negative symptoms of schizophrenia. It's made up of seven items from the PANSS, including: Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic withdrawal, Motor retardation, Active social avoidance, Lack of spontaneity in conversation. Each item is scored from 1 to 7 with a higher score indicating greater severity. Minimum score is 7 and maximum is 49

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
PANSS Negative Factor Score Also Know as Marder Factors
score on a scaleWithania Somnifera Extract (WSE)Placebo Tablets
Baseline2.05 ± .842.68 ± .67
12 weeks2.10 ± .802.45 ± .69

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Withania Somnifera Extract (WSE)0/24 (0%)1/24 (4.2%)12/24 (50%)
Placebo Tablets0/23 (0%)3/23 (13%)18/23 (78.3%)
Most frequent serious events
Most frequent serious events
EventWithania Somnifera Extract (WSE)Placebo Tablets
Suicidal ideationPsychiatric disorders1/242/23
COVID 19Infections and infestations0/241/23
Most frequent other events
Showing 10 of 20
Most frequent other events
EventWithania Somnifera Extract (WSE)Placebo Tablets
Objective tinnitusEar and labyrinth disorders0/242/23
ConstipationGastrointestinal disorders2/241/23
NauseaGastrointestinal disorders2/241/23
Abdominal painGastrointestinal disorders1/241/23
DiarrheaGastrointestinal disorders0/241/23
Dry MouthGastrointestinal disorders1/241/23
Nausea and vomitingGastrointestinal disorders1/241/23
FatigueGeneral disorders0/241/23
EndometritisInfections and infestations0/241/23
Upper Respiratory InfectionInfections and infestations0/241/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Withania Somnifera Extract (WSE)Placebo TabletsTotal
Mean43.7 ± 10.943.8 ± 12.143.7 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Withania Somnifera Extract (WSE)Placebo TabletsTotal
Female639
Male182038
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Withania Somnifera Extract (WSE)Placebo TabletsTotal
Hispanic or Latino123
Not Hispanic or Latino222143
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Withania Somnifera Extract (WSE)Placebo TabletsTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American5914
White161228
More than one race213
Unknown or Not Reported000
08

Study locations

2 sites
  • UCLA
    Los Angeles, California 90095, United States
  • Maryland Psychiatric Research Center
    Catonsville, Maryland 21228, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Deidentified will be submitted an NIH repository

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Jun 2023, 54 months.

Results were first posted in Oct 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 19, 2018
StartActual
Dec 1, 2018
Primary completionActual
Jun 12, 2023
CompletionActual
Jun 12, 2023
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03437668
Lead sponsor
Chengappa, K.N. Roy, MD
Collaborators
Stanley Medical Research Institute, University of Maryland
Responsible party
Stephen Marder (Professor, University of California, Los Angeles) — Principal investigator
First posted
Feb 19, 2018
Start date
Dec 1, 2018
Primary completion
Jun 12, 2023
Completion
Jun 12, 2023
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Study contacts

Stephen Marder, MD
study chair · Semel Inst at UCLA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ashwagandha

Start the discussion